Horm Metab Res 2017; 49(10): 760-771
DOI: 10.1055/s-0043-108911
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

The Correlation Between Circulating Betatrophin and Insulin Resistance in General Population: A Meta-Analysis

Jinling Xu*
1   Department of Endocrinology and Metabolism, Wuhan General Hospital of Chinese People’s Liberation Army, Wuhan 430070, China
,
Yanyan Lin*
1   Department of Endocrinology and Metabolism, Wuhan General Hospital of Chinese People’s Liberation Army, Wuhan 430070, China
,
Hui Zhou
2   Department of General Surgery, Wuhan Third Hospital, Wuhan 430060, China
,
Linshuang Zhao
1   Department of Endocrinology and Metabolism, Wuhan General Hospital of Chinese People’s Liberation Army, Wuhan 430070, China
,
Guangda Xiang
1   Department of Endocrinology and Metabolism, Wuhan General Hospital of Chinese People’s Liberation Army, Wuhan 430070, China
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 28. Januar 2017

accepted 06. April 2017

Publikationsdatum:
20. September 2017 (online)

Zoom Image

Abstract

Many inconsistent findings are reported on the correlation between circulating betatrophin and insulin resistance in the different population. The aim of this analysis was to explore the correlation between the level of betatrophin and insulin resistance in the general population. The databases of PubMed, EMBASE, and the Cochrane Library (inception to October 26, 2016) were searched without language restrictions for publications that reported studies on associations between betatrophin and insulin resistance in adults. Subgroup analyses were performed to investigate potential sources of heterogeneity. The pooled effect size was calculated using a random-effects model. Twenty-five studies were included in this meta-analysis. Meta-analysis showed that betatrophin was positively and significantly correlated with insulin resistance (r=0.16, 95% CI: 0.08–0.25). When all participants were divided into DM, GDM, and Non-DM groups, this association was also significant in T2DM, GDM, and Non-DM participants (T2DM: r=0.09, 95% CI: 0.01–0.17; I 2=45.1%; GDM: r=0.39, 95% CI: 0.24–0.55; I 2=0.0%; non-DM: r=0.15, 95% CI: 0.04–0.26; I 2=89.3%), and it was obvious that heterogeneity existed in Non-DM group (I 2=89.3%, p<0.001). Subgroup analysis revealed that gender, serum sample and ELISA kits for full-length betatrophin had significant influence on the association between betatrophin and insulin resistance. In conclusion, the level of circulating betatrophin is positively associated with insulin resistance in the general population, especially in T2DM and GDM patients. Gender, serum sample, and ELISA kits for full-length betatrophin may affect this association. More large-scale studies are needed to determine whether improving insulin resistance concomitantly declines betatrophin levels in different diseases.

* Contributed equally to this work, co-first authors


Supplementary Material